Acetrizoic acid is a pharmaceutical drug that was used as an iodinated contrast medium for X-ray imaging.[1][2] It was applied in form of its salt, sodium acetrizoate, but is no longer in clinical use.[3]
Clinical data | |
---|---|
Trade names | Urokon, Triurol, Salpix, others |
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.001.455 |
Chemical and physical data | |
Formula | C9H6I3NO3 |
Molar mass | 556.864 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
The substance has high osmolality and is water-soluble. The three iodine atoms in the molecule readily absorb X-rays and are therefore responsible for its usability as a contrast medium.[3]
Acetrizoate was developed by V.H. Wallingford of Mallinckrodt, and introduced in 1950;[4] it was employed as a contrast agent for several radiographic studies, including pyelography,[5][6] angiography of the brain, carotid arteries and the aorta,[7][8] and cholecystography.[9][10] It was soon found to be highly toxic to the kidneys and nervous system—work urging caution in its administration was published as early as 1959,[11] after reports of adverse reactions ranging from hypersensitivity to brain damage—and was eventually replaced by other agents with higher efficacy and lower toxicity, such as sodium diatrizoate, a closely related compound.[4]
Trade names include Urokon, Triurol and Salpix, as well as Gastrografina and Urografina in Portugal.
{{cite journal}}
: Cite journal requires |journal=
(help)